BioSyent Inc. vs Concordia...RX just put up Q4 numbers of 30% Revenue Growth, 58% EBITDA Growth and NO DEBT and 10% of market cap is cash in the bank.
CXR just put up Q4 numbers of declining Revenue and EBITDA and leveraged to the hill.
Choose Accordingly......